Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives Average Recommendation of “Hold” from Brokerages

Posted by Geri Gentry on Jun 25th, 2026

Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH – Get Free Report) (TSE:AUP) have received a consensus rating of “Hold” from the six analysts that are presently covering the company, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $17.25.

Separately, Weiss Ratings downgraded shares of Aurinia Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, May 15th.

View Our Latest Stock Analysis on AUPH

Insider Buying and Selling at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, CEO Kevin Tang bought 206,005 shares of the firm’s stock in a transaction dated Tuesday, June 2nd. The stock was acquired at an average price of $15.28 per share, for a total transaction of $3,147,756.40. Following the completion of the purchase, the chief executive officer owned 13,044,106 shares of the company’s stock, valued at approximately $199,313,939.68. This represents a 1.60% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have bought a total of 814,606 shares of company stock worth $12,455,129 in the last three months. 12.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Arrowstreet Capital Limited Partnership lifted its stake in shares of Aurinia Pharmaceuticals by 0.4% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 3,387,194 shares of the biotechnology company’s stock worth $54,026,000 after acquiring an additional 13,173 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Aurinia Pharmaceuticals by 4.6% in the 1st quarter. Renaissance Technologies LLC now owns 1,663,835 shares of the biotechnology company’s stock worth $24,658,000 after acquiring an additional 73,700 shares during the period. Marshall Wace LLP lifted its stake in shares of Aurinia Pharmaceuticals by 6.2% in the 4th quarter. Marshall Wace LLP now owns 1,574,957 shares of the biotechnology company’s stock worth $25,121,000 after acquiring an additional 91,825 shares during the period. Geode Capital Management LLC lifted its stake in shares of Aurinia Pharmaceuticals by 1.5% in the 4th quarter. Geode Capital Management LLC now owns 1,507,869 shares of the biotechnology company’s stock worth $24,047,000 after acquiring an additional 22,169 shares during the period. Finally, Two Sigma Investments LP lifted its stake in shares of Aurinia Pharmaceuticals by 728.6% in the 3rd quarter. Two Sigma Investments LP now owns 1,341,067 shares of the biotechnology company’s stock worth $14,819,000 after acquiring an additional 1,179,219 shares during the period. Institutional investors and hedge funds own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Stock Up 4.1%

Shares of NASDAQ AUPH opened at $18.62 on Friday. The stock has a market cap of $2.39 billion, a PE ratio of 8.58 and a beta of 1.41. The company has a quick ratio of 5.01, a current ratio of 5.55 and a debt-to-equity ratio of 0.08. Aurinia Pharmaceuticals has a 52-week low of $7.28 and a 52-week high of $19.25. The business has a 50-day moving average price of $15.92 and a 200 day moving average price of $15.33.

Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) (TSE:AUP) last announced its earnings results on Thursday, May 7th. The biotechnology company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.18 by $0.07. The firm had revenue of $77.71 million during the quarter, compared to analysts’ expectations of $76.98 million. Aurinia Pharmaceuticals had a return on equity of 26.62% and a net margin of 99.97%. Equities research analysts forecast that Aurinia Pharmaceuticals will post 0.82 earnings per share for the current year.

About Aurinia Pharmaceuticals

(Get Free Report)

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.